StockNews.com Lowers Dynavax Technologies (NASDAQ:DVAX) to Hold

Dynavax Technologies (NASDAQ:DVAX) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Wednesday.

Several other equities analysts also recently weighed in on DVAX. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. The Goldman Sachs Group began coverage on Dynavax Technologies in a research report on Thursday, February 1st. They set a “neutral” rating and a $20.00 target price on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Dynavax Technologies presently has an average rating of “Moderate Buy” and an average target price of $25.00.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX traded down $0.06 on Wednesday, hitting $11.43. The company had a trading volume of 2,549,852 shares, compared to its average volume of 1,944,944. The company has a current ratio of 13.81, a quick ratio of 12.96 and a debt-to-equity ratio of 0.41. Dynavax Technologies has a 52-week low of $10.06 and a 52-week high of $15.15. The business has a 50 day moving average of $12.41 and a 200 day moving average of $13.35. The company has a market cap of $1.50 billion, a PE ratio of -190.47 and a beta of 1.26.

Insider Transactions at Dynavax Technologies

In other news, CAO Justin Burgess sold 20,526 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 9.31% of the company’s stock.

Hedge Funds Weigh In On Dynavax Technologies

A number of large investors have recently modified their holdings of the company. American Century Companies Inc. grew its stake in shares of Dynavax Technologies by 4.7% in the first quarter. American Century Companies Inc. now owns 86,892 shares of the biopharmaceutical company’s stock valued at $942,000 after buying an additional 3,902 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Dynavax Technologies in the first quarter valued at about $159,000. MetLife Investment Management LLC grew its stake in shares of Dynavax Technologies by 57.4% in the first quarter. MetLife Investment Management LLC now owns 57,543 shares of the biopharmaceutical company’s stock valued at $624,000 after buying an additional 20,984 shares in the last quarter. Allianz Asset Management GmbH grew its stake in shares of Dynavax Technologies by 16.8% in the first quarter. Allianz Asset Management GmbH now owns 59,070 shares of the biopharmaceutical company’s stock valued at $640,000 after buying an additional 8,500 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of Dynavax Technologies by 25.6% in the first quarter. Mackenzie Financial Corp now owns 16,190 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 3,300 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.